Key result
Sotalol use linked to TdP and VF in a patient with pre-existing QTc prolongation.
Case Report (n=1)
Highlights the risk of sotalol exacerbating pre-existing QTc prolongation and causing torsade de pointes.
Reinforces QTc screening before sotalol; this single case leaves open population-level risk quantification.
A case is described of torsade de pointes in a 41 year old woman with pre-existing QTc prolongation, potentially exacerbated by treatment with sotalol. Previous cardiac investigations had been normal and after a second episode of ventricular fibrillation the patient was referred for electrophysiological studies. The authors review the physiology, causes, and treatment of QTc prolongation and torsade de pointes.
No takes yet. Share an insight, caveat, or question.
Philip T. Munro (2002) conducted a case report in Torsade de pointes and QTc prolongation (n=1). Sotalol was evaluated on Torsade de pointes and ventricular fibrillation. A 41-year-old woman with pre-existing QTc prolongation developed torsade de pointes and ventricular fibrillation, potentially exacerbated by sotalol treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: